Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study

Table 2 BMI, CD4 Count and lipid levels at ≥48 weeks on second-line ART

48 weeks after switch to second-line	n (%)	TC mean (se)	^†P	LDL-C mean (se)	^†P	HDL-C mean (se)	^†P	TG mean (se)	^†P	TC/HDL-C ratio mean (se)	^†P
All	65	5.4 (0.2)		2.9 (0.1)		1.2 (0.05)		1.9(0.2)		4.9 (0.3)
Sex
Females	31 (48%)	5.8 (0.2)	0.03	3.2 (0.2)	0.003	1.3 (0.07)	0.03	1.8 (0.2)	0.71	4.6 (0.2)	0.69
Males	34 (52%)	5.1 (0.2)		2.5 (0.1)		1.1 (0.06)		2.0 (0.2)		5.1 (0.4)
BMI (kg/m²)
<18.5	4 (6%)	4.8 (0.4)	0.04	2.6 (0.5)	0.05	1.2 (0.3)	0.57	1.0 (0.2)	0.003	4.6 (0.9)	0.55
18.5-24.9	36 (56%)	5.2 (0.2)		2.7 (0.2)		1.2 (0.1)		1.5 (0.1)		5.0 (0.4)
25-29.9	21 (32%)	5.8 (0.3)		3.1 (0.2)		1.2 (0.1)		2.4 (0.3)		4.8 (0.4)
30-39.9	4 (6%)	5.9 (0.3)		3.1 (0.4)		1.2 (0.4)		2.8 (1.1)		5.0 (1.0)
CD4 cell/mm³
<100	2 (3%)	4.6 (0.9)	0.93	2.6 (0.6)	0.28	1.1 (0.1)	0.10	0.8 (0.02)	0.24	4.2 (1.1)	0.31
100-199	10 (15%)	5.7 (0.2)		3.0 (0.2)		1.4 (0.1)		1.8 (0.5)		4.1 (0.4)
≥200	53 (82%)	5.4 (0.2)		2.8 (0.1)		1.2 (0.1)		1.9 (0.2)		5.1 (0.3)

TC: total cholesterol, LDL-C: low density lipoprotein–cholesterol, HDL-C: high density lipoprotein–cholesterol, TG: triglyceride, BMI: Body mass index. All lipid levels are expressed in mmol/L.
^†P-values for continuous BMI and CD4 vs. lipids calculated using Spearman correlation.

ISSN: 1742-6405